Your browser doesn't support javascript.
loading
Transvenous laser lead extraction in patients with congenital complete heart block.
Darden, Douglas; Boateng, Bendelyn Asante; Tseng, Andrew S; Alshawabkeh, Laith; Pollema, Travis; Cha, Yong-Mei; Birgersdotter-Green, Ulrika.
Afiliação
  • Darden D; Division of Cardiovascular Medicine, University of California San Diego, San Diego, California. Electronic address: djdarden@ucsd.edu.
  • Boateng BA; Division of Cardiovascular Medicine, University of California San Diego, San Diego, California.
  • Tseng AS; Division of Cardiovascular Medicine, Mayo Clinic of Medicine, Rochester, Minnesota.
  • Alshawabkeh L; Division of Cardiovascular Medicine, University of California San Diego, San Diego, California.
  • Pollema T; Division of Cardiovascular Medicine, University of California San Diego, San Diego, California.
  • Cha YM; Division of Cardiovascular Medicine, Mayo Clinic of Medicine, Rochester, Minnesota.
  • Birgersdotter-Green U; Division of Cardiovascular Medicine, University of California San Diego, San Diego, California.
Heart Rhythm ; 19(7): 1158-1164, 2022 07.
Article em En | MEDLINE | ID: mdl-35257976
ABSTRACT

BACKGROUND:

Data on lead management in patients with congenital complete heart block (CCHB) with cardiac implantable electronic devices are lacking.

OBJECTIVE:

The purpose of this study was to describe the natural history and outcomes in patients with CCHB with cardiac implantable electronic devices undergoing transvenous lead extraction (TLE).

METHODS:

Data on all attempted TLE procedures in patients with CCHB at 2 institutions between 2011 and 2021 were collected from a retrospective registry.

RESULTS:

Overall, 16 patients (mean age at transvenous device implant 13.8 ± 4.7 years) were included. Before TLE, patients underwent an average of 2.25 ± 1.3 generator changes, 3 (19%) underwent cardiac resynchronization therapy upgrade, and 7 (44%) underwent a lead revision with subsequently abandoned leads. Mean patient age at TLE was 34.4 ± 9.4 years with a mean duration of lead implant of 19.2 ± 6.9 years. Lead malfunction (n = 11 [69%]) and infection (n = 5 [31%]) were the most common indications for TLE. A total of 38 leads were removed, with complete procedural success achieved in 14 of 16 (87.5%). Two (12.5%) major complications occurred, including right ventricular laceration and superior vena cava tear requiring sternotomies. All patients survived at 1-year follow-up.

CONCLUSION:

Patients with CCHB represent a unique cohort highlighted by several generator changes, lead revisions, and abandoned leads at a young age, along with a long duration of lead dwelling time and a high prevalence of lead malfunction requiring TLE. There may be a high risk of major complications during TLE, suggesting TLE should be performed only in experienced centers. Larger studies are needed to confirm these findings.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Marca-Passo Artificial / Desfibriladores Implantáveis Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Heart Rhythm Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Marca-Passo Artificial / Desfibriladores Implantáveis Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Heart Rhythm Ano de publicação: 2022 Tipo de documento: Article
...